<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Skin and Venereal Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Skin and Venereal Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский журнал кожных и венерических болезней</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1560-9588</issn><issn publication-format="electronic">2412-9097</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">629498</article-id><article-id pub-id-type="doi">10.17816/dv629498</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DERMATOLOGY</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДЕРМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Acne: role of Cutibacterium acnes and possibilities of using bacteriophages</article-title><trans-title-group xml:lang="ru"><trans-title>Акне: роль Cutibacterium acnes и возможности использования бактериофагов</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1450-4942</contrib-id><contrib-id contrib-id-type="spin">6708-7386</contrib-id><name-alternatives><name xml:lang="en"><surname>Bakulev</surname><given-names>Andrey L.</given-names></name><name xml:lang="ru"><surname>Бакулев</surname><given-names>Андрей Леонидович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>al_ba05@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0510-9534</contrib-id><contrib-id contrib-id-type="spin">9206-6186</contrib-id><name-alternatives><name xml:lang="en"><surname>Igonina</surname><given-names>Irina A.</given-names></name><name xml:lang="ru"><surname>Игонина</surname><given-names>Ирина Алексеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>igochka@bk.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-5521-5943</contrib-id><contrib-id contrib-id-type="spin">7922-4120</contrib-id><name-alternatives><name xml:lang="en"><surname>Bocharova</surname><given-names>Yulia M.</given-names></name><name xml:lang="ru"><surname>Бочарова</surname><given-names>Юлия Михайловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>juliavern@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0400-7846</contrib-id><contrib-id contrib-id-type="spin">3289-0591</contrib-id><name-alternatives><name xml:lang="en"><surname>Kravchenya</surname><given-names>Sergey S.</given-names></name><name xml:lang="ru"><surname>Кравченя</surname><given-names>Сергей Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.), Associate Professor</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><email>krawww@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Central State Medical Academy of Department of Presidential Affairs</institution></aff><aff><institution xml:lang="ru">Центральная государственная медицинская академия Управления делами Президента Российской Федерации</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">SB Clinic Cosmetology</institution></aff><aff><institution xml:lang="ru">SB Clinic. Клиника косметологии и дерматологии</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Clinic of Pediatrics and Pediatric Dentistry of Dr. Truhmanov</institution></aff><aff><institution xml:lang="ru">Клиника педиатрии и детской стоматологии доктора Трухманова</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2024-07-03" publication-format="electronic"><day>03</day><month>07</month><year>2024</year></pub-date><pub-date date-type="pub" iso-8601-date="2024-08-04" publication-format="electronic"><day>04</day><month>08</month><year>2024</year></pub-date><volume>27</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>290</fpage><lpage>300</lpage><history><date date-type="received" iso-8601-date="2024-03-27"><day>27</day><month>03</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-06-21"><day>21</day><month>06</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Эко-Вектор</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2027-08-04"/></permissions><self-uri xlink:href="https://rjsvd.com/1560-9588/article/view/629498">https://rjsvd.com/1560-9588/article/view/629498</self-uri><abstract xml:lang="en"><p><italic>BACKGROUND:</italic> The role of <italic>Cutibacterium acnes</italic> in the pathogenesis of acne vulgaris and its adverse effect on follicular hyperkeratosis, inflammation and the skin microbiome have now been established. Their excessive colonization contributes to the loss of microbial diversity of the skin, activates the innate immune system, leads to the appearance of skin rash elements and chronic inflammation. Bacteriophages are considered as a new promising direction in the treatment of patients with acne, as they have an antimicrobial effect against <italic>C. acnes</italic>; contribute to the preservation of the skin microbiome; have an indirect effect on the innate and adaptive immune response.</p> <p><italic>AIM:</italic> To evaluate the effectiveness and safety of topical therapy with cosmetic gel with bacteriophages Fagoderm in the complex treatment of patients with moderate to severe acne.</p> <p><italic>MATERIALS AND METHODS:</italic> In the design of a simple open prospective study in parallel groups, the effect of cosmetic gel with bacteriophages on the number of comedones, pupules and pustules was assessed in 35 adult patients with moderate acne. During therapy, possible adverse events were simultaneously recorded.</p> <p><italic>RESULTS:</italic> During therapy, similar dynamics were noted in the form of a decrease in non-inflammatory elements of acne both in the group of people receiving a combination of adapalene and phagoderm, and in the comparison group, where monotherapy with adapalene was carried out. The number of inflammatory elements of acne decreased in both groups, but in the main group this happened at an earlier time. Compared to the initial data, already in the 2nd week the number of inflammatory elements decreased by 50% (in comparison ― by 32%); by the end of the 4th ― by 95% (respectively in the comparison group ― by 74%).</p> <p><italic>CONCLUSION:</italic> Cosmetic gel with bacteriophages with bacteriophages helps reduce the inflammatory manifestations of moderate acne.</p></abstract><trans-abstract xml:lang="ru"><p>Обоснование. В настоящее время установлена роль <italic>Cutibacterium acnes</italic> в патогенезе обыкновенных угрей, их неблагоприятное влияние на фолликулярный гиперкератоз, воспаление и микробиом кожи. Их избыточная колонизация способствует потере микробного разнообразия кожи, активирует врождённый иммунитет, приводит к появлению элементов кожной сыпи и хронизации воспаления. Бактериофаги рассматриваются как новое перспективное направление терапии пациентов с акне, так как оказывают антимикробное действие в отношении <italic>C. acnes</italic>, косвенное воздействие на врождённый и адаптивный иммунный ответ, а также способствуют сохранению микробиома кожи.</p> <p>Цель исследования ― оценить эффективность и безопасность топической терапии гелем косметическим с бактериофагами Фагодерм в комплексном лечении пациентов с акне средней степени тяжести.</p> <p>Материалы и методы. В дизайне простого открытого проспективного исследования в параллельных группах у 35 взрослых пациентов с акне средней степени тяжести проведена оценка влияния косметического средства с бактериофагами на количество комедонов, папул и пустул. В процессе терапии одновременно регистрировали возможные нежелательные явления.</p> <p>Результаты. В процессе терапии констатировали сходную динамику в виде уменьшения невоспалительных элементов акне как в группе лиц, получавших комбинацию адапалена и фагодерма, так и в группе сравнения, где проводилась монотерапия адапаленом. Число воспалительных элементов акне уменьшалось в обеих группах, однако в основной группе это произошло в более ранние сроки: так, уже на 2-й неделе применения геля число воспалительных элементов уменьшилось по сравнению с исходными данными на 50% (в группе сравнения ― на 32%); к концу 4-й ― на 95% (в группе сравнения ― на 74%).</p> <p>Заключение. Гель косметический с бактериофагами способствует уменьшению воспалительных проявлений акне средней степени тяжести в более ранние сроки в сравнении с монотерапией топическим ретиноидом.</p></trans-abstract><kwd-group xml:lang="en"><kwd>acne vulgaris</kwd><kwd>Cutibacterium acnes</kwd><kwd>therapy</kwd><kwd>bacteriophages</kwd><kwd>cosmetic gel with bacteriophages</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>угри обыкновенные</kwd><kwd>Cutibacterium acnes</kwd><kwd>терапия</kwd><kwd>бактериофаги</kwd><kwd>гель косметический с бактериофагами</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Zouboulis CC, Bettoli V. Management of severe acne. Br J Dermatol. 2015;172(S1):27–36. doi: 10.1111/bjd.13639</mixed-citation><mixed-citation xml:lang="ru">Zouboulis C.C., Bettoli V. Management of severe acne // Br J Dermatol. 2015. Vol. 172, N S1. P. 27–36. doi: 10.1111/bjd.13639</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Dréno B. What is new in the pathophysiology of acne, an overview. J Eur Acad Dermatol Venereol. 2017;31:8–12. doi: 10.1111/jdv.14374</mixed-citation><mixed-citation xml:lang="ru">Dréno B. What is new in the pathophysiology of acne, an overview // J Eur Acad Dermatol Venereol. 2017. Vol. 31. P. 8–12. doi: 10.1111/jdv.14374</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Antiga E, Verdelli A, Bonciani D, et al. Acne: A new model of immune-mediated chronic inflammatory skin disease. G Ital Dermatol Venereol. 2015;150(2):247–254.</mixed-citation><mixed-citation xml:lang="ru">Antiga E., Verdelli A., Bonciani D., et al. Acne: A new model of immune-mediated chronic inflammatory skin disease // G Ital Dermatol Venereol. 2015. Vol. 150, N 2. P. 247–254.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Gollnick HP, Bettoli V, Lambert J, et al. A consensus-based practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol Venereol. 2016;30(9):1480–1490. doi: 10.1111/jdv.13675</mixed-citation><mixed-citation xml:lang="ru">Gollnick H.P., Bettoli V., Lambert J., et al. A consensus-based practical and daily guide for the treatment of acne patients // J Eur Acad Dermatol Venereol. 2016. Vol. 30, N 9. P. 1480–1490. doi: 10.1111/jdv.13675</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Bhat YJ, Latief I, Hassan I. Update on etiopathogenesis and treatment of acne. Indian J Dermatol Venereol Leprology. 2017;83(3):298. doi: 10.4103/0378-6323.199581</mixed-citation><mixed-citation xml:lang="ru">Bhat Y.J., Latief I., Hassan I. Update on etiopathogenesis and treatment of acne // Indian J Dermatol Venereol Leprology. 2017. Vol. 83, N 3. P. 298. doi: 10.4103/0378-6323.199581</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">O’Neill AM, Gallo RL. Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris. Microbiome. 2018;6:177. doi: 10.1186/s40168-018-0558-5</mixed-citation><mixed-citation xml:lang="ru">O’Neill A.M., Gallo R.L. Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris // Microbiome. 2018. Vol. 6. P. 177. doi: 10.1186/s40168-018-0558-5</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Wang D, Duncan B, Li X, Shi J. The role of NLRP3 inflammasome in infection-related, immune-mediated and autoimmune skin diseases. J Dermatological Sci. 2020;98(3):146–151.</mixed-citation><mixed-citation xml:lang="ru">Wang D., Duncan B., Li X., Shi J. The role of NLRP3 inflammasome in infection-related, immune-mediated and autoimmune skin diseases // J Dermatological Sci. 2020. Vol. 98, N 3. P. 146–151.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Platsidaki E, Dessinioti C. Recent advances in understanding Propionibacterium acnes (Cutibacterium acnes) in acne. F1000Res. 2018;7:F1000 Faculty Rev-1953. doi: 10.12688/f1000research.15659.1</mixed-citation><mixed-citation xml:lang="ru">Platsidaki E., Dessinioti C. Recent advances in understanding Propionibacterium acnes (Cutibacterium acnes) in acne // F1000Res. 2018. Vol. 7. P. F1000 Faculty Rev-1953. doi: 10.12688/f1000research.15659.1</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Dréno B, Pécastaings S, Corvec S, et al. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: A brief look at the latest updates. J Eur Acad Dermatol Venereol. 2018;32:5–14. doi: 10.1111/jdv.15043</mixed-citation><mixed-citation xml:lang="ru">Dréno B., Pécastaings S., Corvec S., et al. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: A brief look at the latest updates // J Eur Acad Dermatol Venereol. 2018. Vol. 32. P. 5–14. doi: 10.1111/jdv.15043</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Del Rosso JQ, Kircik LH. The sequence of inflammation, relevant biomarkers, and the pathogenesis of acne vulgaris: What does recent research show and what does it mean to the clinician? J Drugs Dermatol. 2013;12(8, Suppl):s109–115.</mixed-citation><mixed-citation xml:lang="ru">Del Rosso J.Q., Kircik L.H. The sequence of inflammation, relevant biomarkers, and the pathogenesis of acne vulgaris: What does recent research show and what does it mean to the clinician? // J Drugs Dermatol. 2013. Vol. 12, N 8, Suppl. P. s109–115.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Dreno B, Dekio I, Baldwin H, et al. Acne microbiome: From phyla to phylotypes. J Eur Acad Dermatol Venereol. 2024;38(4):657–664. doi: 10.1111/jdv.19540</mixed-citation><mixed-citation xml:lang="ru">Dreno B., Dekio I., Baldwin H., et al. Acne microbiome: From phyla to phylotypes // J Eur Acad Dermatol Venereol. 2024. Vol. 38, N 4. P. 657–664. doi: 10.1111/jdv.19540</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Dagnelie MA, Corvec S, Saint-Jean M, et al. Cutibacterium acnes phylotypes diversity loss: A trigger for skin inflammatory process. J Eur Acad Dermatol Venereol. 2019;33(12):2340–2348. doi: 10.1111/jdv.15795</mixed-citation><mixed-citation xml:lang="ru">Dagnelie M.A., Corvec S., Saint-Jean M., et al. Cutibacterium acnes phylotypes diversity loss: A trigger for skin inflammatory process // J Eur Acad Dermatol Venereol. 2019. Vol. 33, N 12. P. 2340–2348. doi: 10.1111/jdv.15795</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Dagnelie MA, Khammari A, Dréno B, Corvec S. Cutibacterium acnes molecular typing: time to standardize the method. Clin Microbiol Infection. 2018;24(11):1149–1155. doi: 10.1016/j.cmi.2018.03.010</mixed-citation><mixed-citation xml:lang="ru">Dagnelie M.A., Khammari A., Dréno B., Corvec S. Cutibacterium acnes molecular typing: Time to standardize the method // Clin Microbiol Infection. 2018. Vol. 24, N 11. P. 1149–1155. doi: 10.1016/j.cmi.2018.03.010</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Beylot C, Auffret N, Poli F, et al. Propionibacterium acnes: An update on its role in the pathogenesis of acne. J Eur Acad Dermatol Venereol. 2014;28(3):271–278. doi: 10.1111/jdv.12224</mixed-citation><mixed-citation xml:lang="ru">Beylot C., Auffret N., Poli F., et al. Propionibacterium acnes: An update on its role in the pathogenesis of acne // J Eur Acad Dermatol Venereol. 2014. Vol. 28, N 3. P. 271–278. doi: 10.1111/jdv.12224</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Cong TX, Hao D, Wen X, et al. From pathogenesis of acne vulgaris to anti-acne agents. Arch Dermatological Res. 2019;311(5):337–349. doi: 10.1007/s00403-019-01908-x</mixed-citation><mixed-citation xml:lang="ru">Cong T.X., Hao D., Wen X., et al. From pathogenesis of acne vulgaris to anti-acne agents // Arch Dermatological Res. 2019. Vol. 311, N 5. P. 337–349. doi: 10.1007/s00403-019-01908-x</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Farrah G, Tan E. The use of oral antibiotics in treating acne vulgaris: A new approach. Dermatologic Ther. 2016;29(5):377–384.</mixed-citation><mixed-citation xml:lang="ru">Farrah G., Tan E. The use of oral antibiotics in treating acne vulgaris: A new approach // Dermatologic Ther. 2016. Vol. 29, N 5. P. 377–384.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Oudenhoven MD, Kinney MA, McShane DB, et al. Adverse effects of acne medications: Recognition and management. Am J Clin Dermatol. 2015;16(4):231–242. doi: 10.1007/s40257-015-0127-7</mixed-citation><mixed-citation xml:lang="ru">Oudenhoven M.D., Kinney M.A., McShane D.B., et al. Adverse effects of acne medications: Recognition and management // Am J Clin Dermatol. 2015. Vol. 16, N 4. P. 231–242. doi: 10.1007/s40257-015-0127-7</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Liu PF, Hsieh YD, Lin YC, et al. Propionibacterium acnes in the pathogenesis and immunotherapy of acne vulgaris. Curr Drug Metabolism. 2015;16(4):245–254. doi: 10.2174/1389200216666150812124801</mixed-citation><mixed-citation xml:lang="ru">Liu P.F., Hsieh Y.D., Lin Y.C., et al. Propionibacterium acnes in the pathogenesis and immunotherapy of acne vulgaris // Curr Drug Metabolism. 2015. Vol. 16, N 4. P. 245–254. doi: 10.2174/1389200216666150812124801</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Karadag AS, Aslan Kayiran M, Wu CY, et al. Antibiotic resistance in acne: Changes, consequences and concerns. J Eur Acad Dermatol Venereol. 2020;35(1):73–78. doi: 10.1111/jdv.16686</mixed-citation><mixed-citation xml:lang="ru">Karadag A.S., Aslan Kayiran M., Wu C.Y., et al. Antibiotic resistance in acne: Changes, consequences and concerns // J Eur Acad Dermatol Venereol. 2020. Vol. 35, N 1. P. 73–78. doi: 10.1111/jdv.16686</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Woo TE, Sibley CD. The emerging utility of the cutaneous microbiome in the treatment of acne and atopic dermatitis. J Am Acad Dermatol. 2020;82(1):222–228. doi: 10.1016/j.jaad.2019.08.078</mixed-citation><mixed-citation xml:lang="ru">Woo T.E., Sibley C.D. The emerging utility of the cutaneous microbiome in the treatment of acne and atopic dermatitis // J Am Acad Dermatol. 2020. Vol. 82, N 1. P. 222–228. doi: 10.1016/j.jaad.2019.08.078</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Roach DR, Leung CY, Henry M, et al. Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe. 2017;22(1):38–47.e4. doi: 10.1016/j.chom.2017.06.018</mixed-citation><mixed-citation xml:lang="ru">Roach D.R., Leung C.Y., Henry M., et al. Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen // Cell Host Microbe. 2017. Vol. 22, N 1. P. 38–47.e4. doi: 10.1016/j.chom.2017.06.018</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Ilyina TS, Tolordava ER, Romanova YM. A look at phage therapy one hundred years after the bacteriophages discovery. Molecular Genetics, Microbiology and Virology. 2019;37(3):103–112. EDN: FWJUFO doi: 10.17116/molgen201937031103</mixed-citation><mixed-citation xml:lang="ru">Ильина Т.С., Толордава Э.Р., Романова Ю.М. Взгляд на фаготерапию через 100 лет после открытия бактериофагов // Молекулярная генетика, микробиология и вирусология. 2019. Т. 37, № 3. С. 103–112. EDN: FWJUFO doi: 10.17116/molgen201937031103</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Parasion S, Kwiatek M, Gryko R, et al. Bacteriophages as an alternative strategy for fighting biofilm development. Polish J Microbiol. 2014;63(2):137–145.</mixed-citation><mixed-citation xml:lang="ru">Parasion S., Kwiatek M., Gryko R., et al. Bacteriophages as an alternative strategy for fighting biofilm development // Polish J Microbiol. 2014. Vol. 63, N 2. P. 137–145.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Hanlon GW. Bacteriophages: An appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents. 2007;30(2):118–128. doi: 10.1016/j.ijantimicag.2007.04.006</mixed-citation><mixed-citation xml:lang="ru">Hanlon G.W. Bacteriophages: An appraisal of their role in the treatment of bacterial infections // Int J Antimicrob Agents. 2007. Vol. 30, N 2. P. 118–128. doi: 10.1016/j.ijantimicag.2007.04.006</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Jariah RO, Hakim MS. Interaction of phages, bacteria, and the human immune system: Evolutionary changes in phage therapy. Rev Med Virol. 2019;29(5):e2055. doi: 10.1002/rmv.2055</mixed-citation><mixed-citation xml:lang="ru">Jariah R.O., Hakim M.S. Interaction of phages, bacteria, and the human immune system: Evolutionary changes in phage therapy // Rev Med Virol. 2019. Vol. 29, N 5. P. e2055. doi: 10.1002/rmv.2055</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Leung CY, Weitz JS. Modeling the synergistic elimination of bacteria by phage and the innate immune system. J Theor Biol. 2017;429:241–252. doi: 10.1016/j.jtbi.2017.06.037</mixed-citation><mixed-citation xml:lang="ru">Leung C.Y., Weitz J.S. Modeling the synergistic elimination of bacteria by phage and the innate immune system // J Theor Biol. 2017. Vol. 429. P. 241–252. doi: 10.1016/j.jtbi.2017.06.037</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Lenneman BR, Fernbach J, Loessner MJ, et al. Enhancing phage therapy through synthetic biology and genome engineering. Curr Opin Biotechnol. 2021;68:151–159. doi: 10.1016/j.copbio.2020.11.003</mixed-citation><mixed-citation xml:lang="ru">Lenneman B.R., Fernbach J., Loessner M.J., et al. Enhancing phage therapy through synthetic biology and genome engineering // Curr Opin Biotechnol. 2021. Vol. 68. P. 151–159. doi: 10.1016/j.copbio.2020.11.003</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Oechslin F. Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses. 2018;10(7):351. doi: 10.3390/v10070351</mixed-citation><mixed-citation xml:lang="ru">Oechslin F. Resistance development to bacteriophages occurring during bacteriophage therapy // Viruses. 2018. Vol. 10, N 7. P. 351. doi: 10.3390/v10070351</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Kebriaei R, Lev KL, Shah RM, et al. Eradication of biofilm-mediated methicillin-resistant Staphylococcus aureus infections in vitro: Bacteriophage antibiotic combination. Microbiol Spectr. 2022;10(2):e0041122. doi: 10.1128/spectrum.00411-22</mixed-citation><mixed-citation xml:lang="ru">Kebriaei R., Lev K.L., Shah R.M., et al. Eradication of biofilm-mediated methicillin-resistant Staphylococcus aureus infections in vitro: Bacteriophage antibiotic combination // Microbiol Spectr. 2022. Vol. 10, N 2. P. e0041122. doi: 10.1128/spectrum.00411-22</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Brown TL, Petrovski S, Dyson ZA, et al. The formulation of bacteriophage in a semi solid preparation for control of propionibacterium acnes growth. PLoS One. 2016;11(3):e0151184. doi: 10.1371/journal.pone.0151184</mixed-citation><mixed-citation xml:lang="ru">Brown T.L., Petrovski S., Dyson Z.A., et al. The formulation of bacteriophage in a semi solid preparation for control of propionibacterium acnes growth // PLoS One. 2016. Vol. 11, N 3. P. e0151184. doi: 10.1371/journal.pone.0151184</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Kim MJ, Eun DH, Kim SM, et al. Efficacy of bacteriophages in propionibacterium acnes-induced inflammation in mice. Ann Dermatol. 2019;31(1):22–28. doi: 10.5021/ad.2019.31.1.22</mixed-citation><mixed-citation xml:lang="ru">Kim M.J., Eun D.H., Kim S.M., et al. Efficacy of bacteriophages in propionibacterium acnes-induced inflammation in mice // Ann Dermatol. 2019. Vol. 31, N 1. P. 22–28. doi: 10.5021/ad.2019.31.1.22</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Zurabov AYu, Zhilenkov EL, Popov DV, et al. Phagoderm phage preparation and its application perspectives in dermatology and cosmetology. Vestnik esteticheskoi meditsiny. 2012;11(3):56–63. EDN: PFQKCB</mixed-citation><mixed-citation xml:lang="ru">Зурабов А.Ю., Жиленков Е.Л., Попов Д.В., и др. Фаговый препарат «Фагодерм» и перспективы его использования в дерматологии и косметологии // Вестник эстетической медицины. 2012. Т. 11, № 3. С. 56–63. EDN: PFQKCB</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">Zhukova OV, Kasikhina EI, Ostretsova MN, Nemer A. Bacteriophages in the treatment and prevention of atopic dermatitis and dermatoses complicated by secondary bacterial infection. Medical Council. 2022;(13):66–72. EDN: LIHXKN doi: 10.21518/2079-701X-2022-16-13-66-72</mixed-citation><mixed-citation xml:lang="ru">Жукова О.В., Касихина Е.И., Острецова М.Н., Немер А. Бактериофаги в терапии и профилактике атопического дерматита и дерматозов, осложненных вторичной бактериальной инфекцией // Медицинский совет. 2022. Т. 16, № 13. С. 66–72. EDN: LIHXKN doi: 10.21518/2079-701X-2022-16-13-66-72</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">Clinical recommendations. Acne. Moscow; 2016. Available from: https://library.mededtech.ru/rest/documents/cr_721/. Accessed: 15.04.2024.</mixed-citation><mixed-citation xml:lang="ru">Клинические рекомендации Минздрава России. Акне. Москва, 2016. Режим доступа: https://library.mededtech.ru/rest/documents/cr_721/. Дата обращения: 15.04.2024.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
